Fair Value Disclosures | Fair Value Disclosures The following is a summary of our financial assets and liabilities that are accounted for at fair value on a recurring basis, excluding Investments at fair value based on net asset value (“NAV”) of $1.25 billion and $1.21 billion at February 29, 2024 and November 30, 2023, respectively, by level within the fair value hierarchy (in thousands): February 29, 2024 Level 1 Level 2 Level 3 Counterparty Total Assets: Financial instruments owned: Corporate equity securities $ 5,507,909 $ 340,379 $ 173,214 $ — $ 6,021,502 Corporate debt securities — 5,809,579 35,335 — 5,844,914 Collateralized debt obligations and collateralized loan obligations — 782,391 69,367 — 851,758 U.S. government and federal agency securities 2,990,863 107,066 — — 3,097,929 Municipal securities — 275,217 — — 275,217 Sovereign obligations 887,739 651,353 — — 1,539,092 Residential mortgage-backed securities — 1,448,311 684 — 1,448,995 Commercial mortgage-backed securities — 318,198 473 — 318,671 Other asset-backed securities — 140,520 102,256 — 242,776 Loans and other receivables — 1,429,594 78,885 — 1,508,479 Derivatives 310 2,898,300 7,019 (2,213,583) 692,046 Investments at fair value — 6 121,764 — 121,770 Total financial instruments owned, excluding Investments at fair value based on NAV $ 9,386,821 $ 14,200,914 $ 588,997 $ (2,213,583) $ 21,963,149 Securities segregated and on deposit for regulatory purposes or deposited with clearing and depository organizations $ 126,340 $ — $ — $ — $ 126,340 Securities received as collateral 110,897 — — — 110,897 Liabilities: Financial instruments sold, not yet purchased: Corporate equity securities $ 2,954,918 $ 86,820 $ 675 $ — $ 3,042,413 Corporate debt securities — 3,631,375 124 — 3,631,499 Collateralized debt obligations and collateralized loan obligations — 672 — — 672 U.S. government and federal agency securities 2,348,603 — — — 2,348,603 Sovereign obligations 1,091,150 614,857 — — 1,706,007 Commercial mortgage-backed securities — — 944 — 944 Loans — 86,293 1,466 — 87,759 Derivatives 390 3,133,838 59,108 (1,967,283) 1,226,053 Total financial instruments sold, not yet purchased $ 6,395,061 $ 7,553,855 $ 62,317 $ (1,967,283) $ 12,043,950 Other secured financings $ — $ — $ 3,965 $ — $ 3,965 Obligation to return securities received as collateral 110,897 — — — 110,897 Long-term debt — 972,243 779,529 — 1,751,772 (1) Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty. November 30, 2023 (1) Level 1 Level 2 Level 3 Counterparty Total Assets: Financial instruments owned: Corporate equity securities $ 3,831,698 $ 211,182 $ 181,294 $ — $ 4,224,174 Corporate debt securities — 4,921,222 26,112 — 4,947,334 Collateralized debt obligations and collateralized loan obligations — 869,246 64,862 — 934,108 U.S. government and federal agency securities 3,563,164 65,566 — — 3,628,730 Municipal securities — 223,502 — — 223,502 Sovereign obligations 1,051,494 609,452 — — 1,660,946 Residential mortgage-backed securities — 2,048,309 20,871 — 2,069,180 Commercial mortgage-backed securities — 344,902 508 — 345,410 Other asset-backed securities — 255,048 117,661 — 372,709 Loans and other receivables — 1,320,217 130,101 — 1,450,318 Derivatives 314 3,649,814 8,336 (3,107,620) 550,844 Investments at fair value — — 130,835 — 130,835 Total financial instruments owned, excluding Investments at fair value based on NAV $ 8,446,670 $ 14,518,460 $ 680,580 $ (3,107,620) $ 20,538,090 Securities segregated and on deposit for regulatory purposes or deposited with clearing and depository organizations $ 110,198 $ — $ — $ — $ 110,198 Securities received as collateral 8,800 — — — 8,800 Liabilities: Financial instruments sold, not yet purchased: Corporate equity securities $ 2,235,049 $ 83,180 $ 676 $ — $ 2,318,905 Corporate debt securities — 2,842,776 124 — 2,842,900 Collateralized debt obligations and collateralized loan obligations — 36 — — 36 U.S. government and federal agency securities 2,957,787 — — — 2,957,787 Sovereign obligations 1,229,795 579,302 — — 1,809,097 Residential mortgage-backed securities — 463 — — 463 Commercial mortgage-backed securities — — 840 — 840 Loans — 173,828 1,521 — 175,349 Derivatives 54 3,851,004 59,291 (2,764,572) 1,145,777 Total financial instruments sold, not yet purchased $ 6,422,685 $ 7,530,589 $ 62,452 $ (2,764,572) $ 11,251,154 Other secured financings $ — $ — $ 3,898 $ — $ 3,898 Obligation to return securities received as collateral 8,800 — — — 8,800 Long-term debt — 963,846 744,597 — 1,708,443 (1) Excludes amounts for financial instruments reclassified to Assets held for sale and Liabilities held for sale. Refer to Note 5, Assets Held for Sale and Discontinued Operations for further information. (2) Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty. For a description of the valuation basis, including valuation techniques and inputs, used in measuring our financial assets and liabilities that are accounted for at fair value on a recurring basis refer to our consolidated financial statements included in Part II, Item 8 of our Annual Report on Form 10-K for the year ended November 30, 2023. Investments at Fair Value Investments at fair value includes investments in hedge funds and private equity funds, which are measured at the NAV of the funds, provided by the fund managers and are excluded from the fair value hierarchy. Investments at fair value also include direct equity investments in private companies, which are measured at fair value using valuation techniques involving quoted prices of or market data for comparable companies, similar company ratios and multiples ( e.g. , price/EBITDA, price/book value), discounted cash flow analyses and transaction prices observed for subsequent financing or capital issuance by the company. Direct equity investments in private companies are categorized within Level 2 or Level 3 of the fair value hierarchy. The following tables present information about our investments in entities that have the characteristics of an investment company (in thousands): February 29, 2024 Fair Value (1) Unfunded Redemption Frequency Redemption Notice Period Equity Long/Short Hedge Funds (2) $ 316,630 $ — Quarterly (64%) Monthly (36%) 60 - 90 days 60 days Equity Funds (3) 50,224 36,468 N/R (100%) N/R Commodity Funds (4) 20,964 — Quarterly (100%) 60 days Multi-asset Funds (5) 349,971 — Monthly (83%) Quarterly (14%) N/R (3%) 60 days 90 days N/R Other Funds (6) 510,608 131,985 Quarterly (65%) N/R (35%) 90 days N/R Total $ 1,248,397 $ 168,453 November 30, 2023 Fair Value (1) Unfunded Redemption Redemption Equity Long/Short Hedge Funds (2) $ 341,530 $ — Quarterly (57%) N/R (43%) 60 - 90 days N/R Equity Funds (3) 55,701 37,534 N/R (100%) N/R Commodity Funds (4) 21,747 — Quarterly (100%) 60 days Multi-asset Funds (5) 357,445 — Monthly (83%) Quarterly (13%) N/R (4%) 60 days 90 days N/R Other Funds (6) 432,960 132,662 Quarterly (75%) N/R (25%) 90 days N/R Total $ 1,209,383 $ 170,196 N/R - Not redeemable (1) Where fair value is calculated based on NAV, fair value has been derived from each of the funds’ capital statements. (2) Includes investments in hedge funds that invest, long and short, primarily in both public and private equity securities in domestic and international markets. The investments that cannot be redeemed at November 30, 2023, are not redeemable because these investments include restrictions that do not allow for redemption before November 30, 2023 or August 31, 2025. (3) Includes investments in equity funds that invest in the equity of various U.S. and foreign private companies in a broad range of industries. These investments cannot be redeemed; instead, distributions are received through the liquidation of the underlying assets of the funds which are primarily expected to be liquidated in approximately one (4) Includes investments in a hedge fund that invests, long and short, primarily in commodities. (5) Includes investments in hedge funds that invest, long and short, primarily in multi-asset securities in domestic and international markets in both the public and private sectors. The investments that cannot be redeemed at February 29, 2024 and November 30, 2023 are not redeemable because these investments include restrictions that do not allow for redemption before April 1, 2024. (6) Primarily includes investments in a fund that invests in short-term trade receivables and payables that are expected to generally be outstanding between 90 to 120 days and short-term credit instruments, as well as investments in a fund that invests, long and short, in distressed and special situations credit strategies across sectors and asset types. Level 3 Rollforwards The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the three months ended February 29, 2024 (in thousands): Three Months Ended February 29, 2024 Balance at November 30, 2023 Total gains/losses (realized and unrealized) (1) Purchases Sales Settlements Issuances Net transfers into/ Balance at February 29, 2024 For instruments still held at February 29, 2024, changes in unrealized gains (losses) included in: Earnings (1) Other comprehensive income Assets: Financial instruments owned: Corporate equity securities $ 181,294 $ (197) $ 167 $ (265) $ — $ — $ (7,785) $ 173,214 $ (158) $ — Corporate debt securities 26,112 846 20,437 (513) (200) — (11,347) 35,335 801 — CDOs and CLOs 64,862 11,121 16,997 (13,836) (9,539) — (238) 69,367 1,355 — RMBS 20,871 (202) — — (5,360) — (14,625) 684 32 — CMBS 508 (35) — — — — — 473 (64) — Other ABS 117,661 (3,165) 11,686 (17,650) (5,834) — (442) 102,256 (1,468) — Loans and other receivables 130,101 (15,592) 5,477 (24,382) (3,007) — (13,712) 78,885 (17,991) — Investments at fair value 130,835 (10,691) 1,627 — — — (7) 121,764 (10,691) — Liabilities: Financial instruments sold, not yet purchased: Corporate equity securities $ 676 $ (7) $ — $ 6 $ — $ — $ — $ 675 $ 7 $ — Corporate debt securities 124 — — — — — — 124 — — CMBS 840 — (245) 350 — — (1) 944 — — Loans 1,521 (54) (81) — — — 80 1,466 (183) — Net derivatives (2) 50,955 (4,833) — 245 — — 5,722 52,089 4,340 — Other secured financings 3,898 4,482 — — (4,415) — — 3,965 (4,482) — Long-term debt 744,597 12,284 — — — 21,456 1,192 779,529 (14,477) 2,193 (1) Realized and unrealized gains/losses are primarily reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes within Long-term debt are presented net of tax in our Consolidated Statements of Comprehensive Income. (2) Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives. Analysis of Level 3 Assets and Liabilities for the Three Months Ended February 29, 2024 During the three months ended February 29, 2024, transfers of assets of $11.2 million from Level 2 to Level 3 of the fair value hierarchy are primarily attributed to: • Loan and other receivables of $6.5 million, Other ABS of $1.7 million, Corporate debt securities of $1.7 million and Corporate equity securities of $1.3 million due to reduced pricing transparency. During the three months ended February 29, 2024, transfers of assets of $59.4 million from Level 3 to Level 2 of the fair value hierarchy are primarily attributed to: • Loans and other receivables of $20.2 million, RMBS of $14.6 million, Corporate debt securities of $13.0 million, Corporate equity securities of $9.1 million and Other ABS of $2.2 million due to greater pricing transparency supporting classification into Level 2. During the three months ended February 29, 2024, transfers of liabilities of $31.6 million from Level 2 to Level 3 of the fair value hierarchy are primarily attributed to: • Structured notes within Long-term debt of $16.1 million and Net derivatives of $15.4 million due to reduced market and pricing transparency. During the three months ended February 29, 2024, transfers of liabilities of $24.6 million from Level 3 to Level 2 of the fair value hierarchy are primarily attributed to: • Structured notes within Long-term debt of $14.9 million and Net derivatives of $9.7 million due to greater pricing and market transparency. Net losses on Level 3 assets were $17.9 million and net losses on Level 3 liabilities were $11.9 million for the three months ended February 29, 2024. Net losses on Level 3 assets were primarily due to decreased market values across Loans and other receivables, Investments at fair value and Other ABS, partially offset by increased valuations of CDOs and CLOs. Net losses on Level 3 liabilities were primarily due to increased valuations of structured notes within Long-term debt and Other secured financings, partially offset by decreases in certain derivatives. The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the three months ended February 28, 2023 (in thousands): Three Months Ended February 28, 2023 Balance at November 30, 2022 Total gains/losses (realized and unrealized) (1) Purchases Sales Settlements Issuances Net transfers into/ Balance at February 28, 2023 For instruments still held at February 28, 2023, changes in unrealized gains (losses) included in: Earnings (1) Other comprehensive income Assets: Financial instruments owned: Corporate equity securities $ 240,347 $ 17,688 $ — $ (297) $ — $ — $ 3,896 $ 261,634 $ 17,648 $ — Corporate debt securities 30,232 (1,715) 3,147 (7,305) (200) — 17,634 41,793 (1,834) — CDOs and CLOs 55,824 4,810 36,441 (15,666) (8,971) — — 72,438 (2,985) — RMBS 27,617 (3,605) — — (25) — — 23,987 (2,868) — CMBS 839 (353) — — — — — 486 (356) — Other ABS 94,677 (2,940) 13,740 — (5,959) — 910 100,428 (1,716) — Loans and other receivables 168,875 446 3,267 (10,160) (8) — (13,747) 148,673 38 — Investments at fair value 161,992 (2,636) 5,637 (2,420) (4,710) — — 157,863 (2,636) — Liabilities: Financial instruments sold, not yet purchased: Corporate equity securities $ 750 $ (135) $ — $ 13 $ — $ — $ — $ 628 $ 135 $ — Corporate debt securities 500 (28) (187) — — — — 285 28 — CMBS 490 — — 35 — — — 525 525 — Loans 3,164 120 (211) — — — (28) 3,045 (199) — Net derivatives (2) 59,524 9,713 — 127 (537) — 18,504 87,331 (10,352) — Other secured financings 1,712 — — — — — — 1,712 — — Long-term debt 661,123 19,877 — — — 203 2,495 683,698 15,593 (35,470) (1) Realized and unrealized gains/losses are primarily reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes within Long-term debt are presented net of tax in our Consolidated Statements of Comprehensive Income. (2) Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives. Analysis of Level 3 Assets and Liabilities for the Three Months Ended February 28, 2023 During the three months ended February 28, 2023, transfers of assets of $39.8 million from Level 2 to Level 3 of the fair value hierarchy are primarily attributed to: • Corporate debt securities of $17.7 million, Loans and other receivables of $13.9 million, Corporate equity securities of $4.3 million and Other ABS of $3.9 million due to reduced pricing transparency. During the three months ended February 28, 2023, transfers of assets of $31.1 million from Level 3 to Level 2 of the fair value hierarchy are primarily attributed to: • Loans and other receivables of $27.7 million and Other ABS of $3.0 million due to greater pricing transparency supporting classification into Level 2. During the three months ended February 28, 2023, transfers of liabilities of $58.2 million from Level 2 to Level 3 of the fair value hierarchy are primarily attributed to: • Net derivatives of $34.1 million and structured notes within Long-term debt of $24.1 million due to reduced market and pricing transparency. During the three months ended February 28, 2023, transfers of liabilities of $37.2 million from Level 3 to Level 2 of the fair value hierarchy are primarily attributed to: • Structured notes within Long-term debt of $21.6 million and net derivatives of $15.6 million due to greater pricing and market transparency. Net gains on Level 3 assets were $11.7 million and net losses on Level 3 liabilities were $29.5 million for the three months ended February 28, 2023. Net gains on Level 3 assets were primarily due to increased market values across Corporate equity securities and CDOs and CLOs, partially offset by decreases in RMBS, Other ABS, Investments at fair value and Corporate debt securities. Net losses on Level 3 liabilities were primarily due to decreased valuations of structured notes within Long-term debt and certain derivatives. Quantitative Information about Significant Unobservable Inputs used in Level 3 Fair Value Measurements at February 29, 2024 and November 30, 2023 The tables below present information on the valuation techniques, significant unobservable inputs and their ranges for our financial assets and liabilities, subject to threshold levels related to the market value of the positions held, measured at fair value on a recurring basis with a significant Level 3 balance. The range of unobservable inputs could differ significantly across different firms given the range of products across different firms in the financial services sector. The inputs are not representative of the inputs that could have been used in the valuation of any one financial instrument ( i.e., the input used for valuing one financial instrument within a particular class of financial instruments may not be appropriate for valuing other financial instruments within that given class). Additionally, the ranges of inputs presented below should not be construed to represent uncertainty regarding the fair values of our financial instruments; rather, the range of inputs is reflective of the differences in the underlying characteristics of the financial instruments in each category. For certain categories, we have provided a weighted average of the inputs allocated based on the fair values of the financial instruments comprising the category. We do not believe that the range or weighted average of the inputs is indicative of the reasonableness of uncertainty of our Level 3 fair values. The range and weighted average are driven by the individual financial instruments within each category and their relative distribution in the population. The disclosed inputs when compared with the inputs as disclosed in other periods should not be expected to necessarily be indicative of changes in our estimates of unobservable inputs for a particular financial instrument as the population of financial instruments comprising the category will vary from period to period based on purchases and sales of financial instruments during the period as well as transfers into and out of Level 3 each period. February 29, 2024 Financial Instruments Owned: Fair Value Valuation Technique Significant Unobservable Input(s) Input / Range Weighted Corporate equity securities $ 173,214 Non-exchange-traded securities Market approach Price $0 - $325 $61 Corporate debt securities $ 35,335 Scenario analysis Estimated recovery percentage 4% — Market approach Price $42 - $102 $85 CDOs and CLOs $ 54,253 Discounted cash flows Constant prepayment rate 20% — Constant default rate 2% — Loss severity 30% — Discount rate/yield 13 % - 23% 19% Market approach Price $51 - $106 $92 Other ABS $ 88,370 Discounted cash flows Discount rate/yield 9 % - 20% 17% Cumulative loss rate 9 % - 32% 26% Duration (years) 0.9 - 2.2 1.7 Market approach Price $100 — Loans and other receivables $ 73,810 Market approach Price $34 - $125 $84 Scenario analysis Estimated recovery percentage 7 % - 100% 66% Derivatives $ 3,393 Equity options Volatility benchmarking Volatility 64.5 — Investments at fair value $ 117,620 Private equity securities Market approach Price $1 - $7,760 $565 Discount rate/yield 28% — Revenue $30,393,087 — Financial Instruments Sold, Not Yet Purchased: Corporate debt securities $ 124 Scenario analysis Estimated recovery percentage 4% — Derivatives $ 57,337 Equity options Volatility benchmarking Volatility 31.8 - 112.5 47.6 Embedded options Market approach Basis points upfront 0.2 - 24.3 16.2 Other secured financings $ 3,965 Scenario analysis Estimated recovery percentage 60 % - 100% 93% Long-term debt $ 779,529 Structured notes Market approach Price $58 - $117 $83 Price €65 - €105 €87 November 30, 2023 Financial Instruments Owned: Fair Value Valuation Technique Significant Unobservable Input(s) Input / Range Weighted Corporate equity securities $ 181,294 Non-exchange-traded securities Market approach Price $0 - $325 $59 Corporate debt securities $ 26,112 Market approach Price $40 - $94 $50 Discounted cash flows Discount rate/yield 11% — Scenario analysis Estimated recovery percentage 4% — CDOs and CLOs $ 64,862 Discounted cash flows Constant prepayment rate 15 % - 20% 19% Constant default rate 2% — Loss severity 35 % - 40% 36% Discount rate/yield 21 % - 26% 24% Market approach Price $48 - $100 $88 CMBS $ 508 Scenario analysis Estimated recovery percentage 28% — Other ABS $ 102,423 Discounted cash flows Discount rate/yield 10 % - 21% 18% Cumulative loss rate 9 % - 32% 25% Duration (years) 1.1 - 2.2 1.7 Market approach Price $100 — Loans and other receivables $ 130,101 Market approach Price $82 - $157 $127 Scenario analysis Estimated recovery percentage 7 % - 73% 40% Derivatives $ 2,395 Equity options Volatility benchmarking Volatility 60% — Investments at fair value $ 127,237 Private equity securities Market approach Price $1 - $6,819 $484 Discount rate/yield 28% — Revenue $30,538,979 — Financial Instruments Sold, Not Yet Purchased: Corporate debt securities $ 124 Scenario analysis Estimated recovery percentage 4% — Loans $ 1,521 Market approach Price $101 — Derivatives $ 56,779 Equity options Volatility benchmarking Volatility 31 % - 87% 42% Embedded options Market approach Basis points upfront 0.4 - 25.5 17.9 Other secured financings $ 3,898 Scenario analysis Estimated recovery percentage 18 % - 73% 53% Long-term debt $ 744,597 Structured notes Market approach Price $57 - $114 $78 Price €60 - €103 €84 The fair values of certain Level 3 assets and liabilities that were determined based on third-party pricing information, unadjusted past transaction prices or a percentage of the reported enterprise fair value are excluded from the above tables. At February 29, 2024 and November 30, 2023, asset exclusions consisted of $43.0 million and $45.6 million, respectively, primarily comprised of CDOs and CLOs, Other ABS, Loans and other receivables, Investments at Fair Value, certain derivatives, RMBS and CMBS. At February 29, 2024 and November 30, 2023, liability exclusions consisted of $4.9 million and $4.0 million, respectively, primarily comprised of certain derivatives, loans, CMBS and corporate equity securities. Uncertainty of Fair Value Measurement from Use of Significant Unobservable Inputs For recurring fair value measurements categorized within Level 3 of the fair value hierarchy, the uncertainty of the fair value measurement due to the use of significant unobservable inputs and interrelationships between those unobservable inputs (if any) are described below: • Non-exchange-traded securities, corporate debt securities, CDOs and CLOs, loans and other receivables, other ABS, private equity securities, certain derivatives and structured notes using a market approach valuation technique. A significant increase (decrease) in the price of the private equity securities, non-exchange-traded securities, corporate debt securities, CDOs and CLOs, other ABS, loans and other receivables or structured notes would result in a significantly higher (lower) fair value measurement. A significant increase (decrease) in the revenue multiple related to private equity securities would result in a significantly higher (lower) fair value measurement. A significant increase (decrease) in the discount rate/security yield related to private equity securities would result in a significantly lower (higher) fair value measurement. Depending on whether we are a receiver or (payer) of basis points upfront, a significant increase in basis points would result in a significant increase (decrease) in the fair value measurement of options. • Loans and other receivables, corporate debt securities, CMBS and other secured financings using scenario analysis. A significant increase (decrease) in the possible recovery rates of the cash flow outcomes underlying the financial instrument would result in a significantly higher (lower) fair value measurement for the financial instrument. • CDOs and CLOs, corporate debt securities and other ABS using a discounted cash flow valuation technique. A significant increase (decrease) in isolation in the constant default rate, loss severity or cumulative loss rate would result in a significantly lower (higher) fair value measurement. The impact of changes in the constant prepayment rate and duration would have differing impacts depending on the capital structure and type of security. A significant increase (decrease) in the discount rate/security yield would result in a significantly lower (higher) fair value measurement. • Derivative equity options using volatility benchmarking. A significant increase (decrease) in volatility would result in a significantly higher (lower) fair value measurement. Fair Value Option Election For a description of our financial assets and liabilities we have elected the fair value option refer to our consolidated financial statements included in Part II, Item 8 of our Annual Report on Form 10-K for the year ended November 30, 2023. The following is a summary of gains (losses) due to changes in fair value related to instrument-specific credit risk on loans, other receivables and debt instruments and gains (losses) due to other changes in fair value on Long-term debt measured at fair value under the fair value option (in thousands): Three Months Ended February 29, 2024 February 28, 2023 Financial instruments owned: Loans and other receivables $ (7,410) $ 7,454 Other secured financings: Other changes in fair value (2) $ (4,482) $ — Long-term debt: Changes in instrument-specific credit risk (1) $ (3,980) $ (71,660) Other changes in fair value (2) (43,817) 45,825 (1) Changes in fair value of structured notes related to instrument-specific credit risk are presented net of tax in our Consolidated Statements of Comprehensive Income. (2) Other changes in fair value are included in Principal transactions revenues in our Consolidated Statements of Earnings. The following is a summary of the amounts by which contractual principal is greater than (less than) fair value for loans and other receivables, Other secured financings and Long-term debt measured at fair value under the fair value option (in thousands): February 29, 2024 November 30, 2023 Financial instruments owned: Loans and other receivables (1) $ 1,975,612 $ 2,344,468 Loans and other receivables on nonaccrual status and/or 90 days or greater past due (1) (2) 253,784 259,354 Long-term debt 248,547 294,256 Other secured financings 459 1,377 (1) Interest income is recognized separately from other changes in fair value and is included in Interest revenues in our Consolidated Statements of Earnings. (2) Amounts include loans and other receivables 90 days or greater past due by which contractual principal exceeds fair value of $146.8 million and $187.4 million at February 29, 2024 and November 30, 2023, respectively. The aggregate fair value of loans and other receivables on nonaccrual status and/or 90 days or greater past due was $67.3 million and $98.1 million at February 29, 2024 and November 30, 2023, respectively, which includes loans and other receivables 90 days or greater past due of $54.0 million and $37.6 million at February 29, 2024 and November 30, 2023, respectively. Assets Measured at Fair Value on a Non-recurring Basis Certain assets were measured at fair value on a non-recurring basis and are not included in the tables above. Impairment losses for the three months ended February 28, 2023 attributable to an equity method investment were $22.1 million and were recognized in Other revenues in our Consolidated Statements of Earnings. The assets of the equity method investment were included within the Asset Management reportable business segment. At November 30, 2023, the equity method investment had a fair value of zero and would be categorized within Level 3 of the fair value hierarchy. Fair value at February 29, 2024 was based on our best estimate of what could be recognized in a sale transaction for the investment. During the three months ended February 29, 2024, our shares in Monashee, an equity method investment, were converted to a newly created class of nonmarketable preferred shares. Our equity method investment was remeasured to a fair value of $21.9 million in connection with its nonmonetary exchange into the preferred shares. Financial Instruments Not Measured at Fair Value Certain of our financial instruments are not carried at fair value but are recorded at amounts that approximate fair value due to their liquid or short-term nature and generally negligible credit risk. These financial assets include Cash and cash equivalents and Cash and securities segregated and on deposit for regulatory purposes or deposited with clearing and depository organizations and would generally be presented within Level 1 of the fair value hierarchy. We have equity securities without readily determinable fair values, which we account for at cost, minus impairment, which are presented within Other assets in our Consolidated Statements of Financial Condition and were $21.9 million and 0.0 million at February 29, 2024 and November 30, 2023, respectively. Net losses of $33.2 million were recognized on these investments during the three months ended February 28, 2023. There were no impairments on these investments during the three months ended February 29, 2024 and February 28, 2023. |